Muscarinic acetylcholine receptor antagonists
Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.
1. The compound which is 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide.
2. A pharmaceutical composition comprising 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide and a pharmaceutically acceptable carrier thereof.
3. The compound
wherein
X is a pharmaceutically acceptable anion.
4. The compound according to claim 3 wherein the pharmaceutically acceptable anion is chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate.
5. The compound according to claim 3 wherein the pharmaceutically acceptable anion is bromide.
6. The compound according to claim 3 wherein the pharmaceutically acceptable anion is iodide.
7. A pharmaceutical composition comprising the compound
wherein
X is a pharmaceutically acceptable anion, and a pharmaceutically acceptable carrier thereof.
8. The composition according to claim 7 wherein the pharmaceutically acceptable anion is chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate.
9. The composition according to claim 7 wherein the pharmaceutically acceptable anion is bromide.
10. The composition according to claim 7 wherein the pharmaceutically acceptable anion is iodide.
11. A pharmaceutical composition according to claim 2 in a form suitable for administration by oral or nasal inhalation.
12. A pharmaceutical composition according to claim 11 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, multi-dose dry powder inhaler, or a metered dose inhaler.
13. A pharmaceutical composition according to claim 2 which is a dry powder composition.
14. A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable carrier is lactose.
15. A pharmaceutical composition according to claim 7 in a form suitable for administration by oral or nasal inhalation.
16. A pharmaceutical composition according to claim 15 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler.
17. A pharmaceutical composition according to claim 7 which is a dry powder composition.
18. A pharmaceutical composition according to claim 7 wherein the pharmaceutically acceptable carrier is lactose.